<DOC>
	<DOCNO>NCT01215955</DOCNO>
	<brief_summary>Evidence regard optimal method insulin dose adjustment lack literature . The purpose study evaluate efficacy safety two approach escalate prandial insulin therapy participant type 2 diabetes mellitus achieve adequate glycemic control basal insulin .</brief_summary>
	<brief_title>Study Insulin Lispro Participants With Inadequately Controlled Type 2 Diabetes</brief_title>
	<detailed_description>Participants enter study already take insulin glargine screen HbA1c &gt; 7.0 % randomize one two treatment arm . Both arm add prandial insulin exist basal insulin therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have type 2 diabetes Have treat least 90 day insulin glargine , neutral protamine Hagedorn ( NPH ) , detemir combination oral antihyperglycemic agent monotherapy , dual , triple therapy [ sulfonylurea , meglitinide , metformin , pioglitazone , dipeptidyl peptidase4 ( DPP4 ) inhibitor ] opinion investigator require intensification therapy Are treat insulin glargine , NPH , detemir least 20 unit per day ( U/day ) enrollment Have glycated hemoglobin ( HbA1c ) value great 7.0 % less equal 12.0 % accord central laboratory screen Capable willing following : inject insulin prefilled pen , perform self blood glucose monitoring record keep require protocol , determine investigator Have give write informed consent participate study accordance local regulation Prior rapid shortacting insulin therapy : participant receive schedule longterm shortacting rapidacting premixed insulin therapy within past 6 month eligible participate study . Participants previously receive short rapidacting insulin part shortterm insulin therapy ( gestational diabetes , acute hospitalization illness ) occasional use allow participate study . Occasional use ( e.g. , use treat acute hyperglycemia ) shall define less daily administration 1 dose per day short rapidacting insulin Concomitant medication : glucagonlike peptide1 ( GLP1 ) receptor agonist , alphaglucosidase inhibitor , rosiglitazone use concurrently within 3 month prior entry study Severe hypoglycemia : one episode severe hypoglycemia ( define require assistance third party due disable hypoglycemia ) within 6 month prior entry study Excessive insulin resistance : receive total daily dose insulin great 2.0 unit per kilogram ( U/kg ) time randomization Morbid obesity : define body mass index great equal 45 kilogram per square meter ( kg/mÂ² ) Malignancy : active untreated malignancy , remission clinically significant malignancy ( basal cell squamous cell skin cancer ) less 5 year Cardiovascular : cardiac disease functional status New York Heart Association Class III IV ( see New York Heart Association Cardiac Disease Classifications ) Congestive Heart Failure ( CHF ) require pharmacologic treatment , investigator 's opinion , severe dependent edema ( i.e. , edema foot ankle ) condition associate hypoperfusion , hypoxemia , dehydration , sepsis Renal : history renal transplantation currently receive renal dialysis serum creatinine great equal 2 milligram per deciliter ( mg/dL ) metformin Hepatic : obvious clinical sign symptom liver disease , acute chronic hepatitis , alanine aminotransferase/serum glutamic pyruvic transaminase ( ALT/SGPT ) great 3 time upper limit reference range define central laboratory Hematologic : know hemoglobinopathy chronic anemia know blood disorder Reproductive : ( woman ) pregnant intend become pregnant course study ; sexually active woman childbearing potential actively practice birth control method determine investigator medically acceptable ; breastfeed Allergy : know allergy insulin lispro , insulin glargine , excipients contain product Glucocorticoid therapy : receiving chronic ( lasting longer 2 week ) systemic glucocorticoid therapy ( exclude topical inhale preparation ) receive therapy within 2 week immediately screen Adherence protocol : condition ( include know drug alcohol abuse psychiatric disorder ) preclude participant follow complete protocol Prior participation : currently enrol , participate , interventional medical , surgical , pharmaceutical drug device offlabel use study ( investigational study medical surgical treatment give ) within 30 day prior entry study , person previously complete withdrawn study ( sign inform consent document ) . Participants may ineligible concurrently enrol type medical research judge scientifically medically compatible study Nonapproved drug : treat drug within last 30 day receive regulatory approval time study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Insulin</keyword>
	<keyword>Algorithms</keyword>
	<keyword>Blood glucose level</keyword>
</DOC>